Companies›Healthcare›Healthcare›Pharmaceuticals & Biotechnology
NSE:PFIZER

PFIZER LTD

Healthcare › Pharmaceuticals & Biotechnology·NIFTY MICROCAP 250NIFTY SMALLCAP 500NIFTY TOTAL MARKET
₹3,718.00
at close · 27 Oct 2026
▲ 23.00 (+0.62%)
ThemesBiotechnology· growingArtificial Intelligence· mention

Latest filings

Next results: Tue, 3 Nov · Financial Results
  1. Board meeting set for November 3 to approve quarterly and half-year results · Results
  2. Pfizer files quarterly dematerialization compliance certificate · Compliance
  3. Newspaper ad on SEBI special window for physical share transfers · Compliance
All filings ↓
Ask Nexa about PFIZER LTD

Snapshot

What the business is, and whether it's a good one at a fair price.

AI · written from filings

Sells pharmaceutical products in India, generating Rs 2,519.65 crore in revenue in FY26, up 10.4% year-on-year with net profit of Rs 722.43 crore. The product range includes the hormone-based menopause therapy Premarin Vaginal Cream, an imported product that contributes less than 1% of revenue. Q1 FY27 revenue was Rs 653.17 crore, up 8.3% year-on-year, with net profit of Rs 204.47 crore. Employee costs are the largest operating expense at 14.6% of revenue, with materials at 12.3% and other operating expenses at 14.4%. Capital expenditure was 1.0% of revenue in FY26, and the company has no subsidiaries, has operated for 75 years, and declared a Rs 75 per share dividend for the year.

Operating scale
FY26 revenue from operations
Rs 2,519.65 croreFY26
FY26 net profit
Rs 722.43 croreFY26
Q1 FY27 revenue from operations
Rs 653.17 crore (up 8.3% YoY)Q1 FY27
Q1 FY27 net profit
Rs 204.47 crore (up 6.6% YoY)Q1 FY27
Years in operation
75 years (75th AGM in FY26)
Final dividend declared
Rs 75 per share (750% on face value)FY26
Who pays it
Doctors, hospitals, pharmacies and patients in India through pharmaceutical sales channels.
Biggest cost
Employee cost at 14.6% of revenue is the single largest line in FY26 cost shape, ahead of materials at 12.3% and other opex at 14.4%.
Kind of business
Established, asset-light Indian pharmaceutical company that imports and sells products; no subsidiaries.
Where it sits
Listed Indian pharmaceutical company in Healthcare/Pharmaceuticals & Biotechnology; has 75 years of operating history and no subsidiaries per its latest secretarial compliance report.
Market Cap
₹17,010 Cr
P / E (TTM)
18.4×
EV / EBITDA
12.7×
Div Yield
4.42%
Growth
2.4%▲
Revenue 5y CAGR
PAT +7.7% · EBITDA +5.6%
Quality
23.6%▲
ROCE (5y median)
ROE 18.2% (5y median) · margin 41.4%
Leverage
0.00·
Debt / Equity · low
Net cash ₹100 Cr
Revenue FY21→FY26
1.1×▲
Margin +6.4 pts
₹2,239 Cr → ₹2,520 Cr
Cash conversion
0.89×·
Operating cash ÷ profit · 5 yrs
₹2,907 Cr on ₹3,278 Cr
Moves on a normal day
0.91%·
Median daily move
Last 267 sessions · the yardstick for filing-day moves
Where it sits among 185 Pharmaceuticals peersBar = share of peers beaten · tick = industry median · latest reported figures
P/E (TTM)#45/158
P/B#100/163
ROCE#22/183
ROE#33/166
Debt / Equity#37/166
EBITDA margin#6/165
Revenue growth#100/161
Profit growth#104/158

Scorecard

Measured from the filed financials, judged against its Pharmaceuticals peers · as of FY26 — not investment advice

Strengths
Returns on capital 23.6% (5-year median)
#22 of 183 in Pharmaceuticals on the latest reported figures · down from 27.4% in FY21
Debt at 0.00× equity
lower than 78% of its 166 Pharmaceuticals peers
Concerns
Slow revenue growth — 2% a year over 5 years

Charts

How has the market priced it — with filings on the timeline?

PFIZER · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Peers

How does it stack up on valuation, returns and growth?

Loading peers…

Financials

Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.

Loading financials…

Ownership

Who owns it — and is the promoter stake clean?

Loading shareholding…

Sign up to see the full company file

Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.

Common questions

Answered from PFIZER LTD's filed financials and exchange disclosures

What does PFIZER LTD do?

PFIZER LTD is a Pharmaceuticals & Biotechnology company listed on NSE and BSE, trading under the symbol PFIZER.

Is PFIZER LTD profitable?

Yes. Over the trailing twelve months PFIZER LTD reported a net profit of ₹927 Cr on revenue of ₹3,173 Cr.

Does PFIZER LTD pay a dividend?

Yes. The dividend yield is 4.42% at the current price. It paid out 104% of its profit as dividend in FY26.

Is PFIZER LTD debt-free?

On a net basis, yes. It reported borrowings of ₹2.50 Cr on its 31 Mar 2026 balance sheet, but holds ₹100 Cr more cash than debt.

Is PFIZER LTD expensive compared with its peers?

On trailing P/E, PFIZER LTD ranks 45 of 158 in Pharmaceuticals — cheaper than 72% of them, against an industry median of 30.1×. This is a position, not a valuation judgement.

How much does the PFIZER LTD share price move in a day?

On a typical session PFIZER LTD moves 0.91% — that is the median absolute close-to-close move across its last 267 trading days. MarketPing measures each filing's price reaction against it.

When are PFIZER LTD's next results?

Financial Results on Tue, 3 Nov. MarketPing alerts you on WhatsApp the moment the filing lands.

Where can I track PFIZER LTD's announcements?

Every NSE and BSE filing by PFIZER LTD appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.

Figures are as last reported and may lag the latest filing. Not investment advice.